Eli Lilly and Company’s (Lilly) oncology unit Loxo@Lilly has secured the US Food and Drug Administration (FDA) approval for Jaypirca (pirtobrutinib) to treat relapsed or refractory mantle cell lymphoma (MCL).

Jaypirca has been approved to treat MCL in adult patients who had previously received a minimum of two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.

It is a highly selective, non-covalent (reversible) BTK inhibitor of the enzyme and uses a new binding mechanism.

Jaypirca works to re-establish BTK inhibition in MCL patients who have previously received treatment with a covalent BTK inhibitor, including ibrutinib, acalabrutinib, or zanubrutinib.

It is now approved under the FDA’s Accelerated Approval pathway based on the response rate from a patients’ subset in the Phase I/II BRUIN trial.

Lilly stated that the continued approval of Jaypirca for this indication is based on clinical benefit in a confirmatory trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Loxo@Lilly CEO Jacob Van Naarden said: “We are pleased to bring a meaningful new therapeutic option to patients with MCL that can re-establish the benefit of targeting the BTK pathway after receiving multiple prior therapies, including a covalent BTK inhibitor.

“We are grateful to the patients, investigators, and other members of the clinical care teams for their contributions.

“Our team has been committed to rapidly advancing the development of Jaypirca for patients with MCL, and we look forward to building on this milestone by continuing to bring forward important new treatments for people with haematologic malignancies.”

The ongoing, multi-centre, first-in-human, global BRUIN trial of Jaypirca is being conducted in people with hematologic malignancies, including MCL.

In the trial, 583 haematological malignancy patients received Jaypirca 200mg once a day, and the efficacy of the drug was assessed in 120 MCL patients.

The findings showed that 83% of patients taking Jaypirca discontinued their last BTK inhibitor due to refractory or progressive disease.

Furthermore, the company intends to commercialise the drug in the country within a few weeks.